Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageICON is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. We offer a full range of clinical, consulting and commercial services that range from clinical development strategy, planning and trial design, to full study execution, and post-market commercialization. ICON provides its services across a range of clinical outsourcing operating models including strategic partnerships, preferred provider, full-service delivery to functional service provision and stand-alone services.
In the company’s own words · 20-F filed May 27, 2026 · SEC EDGAR
ICON Public Limited Company (ICLR) reported revenue of $2.03B in Q1 2026 (quarter ended March 31, 2026), up 0.9% from the same quarter a year earlier. That came with a gross margin of 23% and net income of $105M (5.2% of revenue). For the full year FY2025, revenue was $8.25B (+0.8% year on year) and net income $229M.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #25 of 29 by Smart Score